Could a gene flaw weaken immunity in Alpha-1 patients?
NCT ID NCT07135427
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to understand why some people with alpha-1 antitrypsin deficiency (AATD) get more respiratory infections. Researchers will compare immune responses to a pneumonia vaccine (PCV20) in 30 adults who carry one abnormal copy of the SERPINA1 gene. Half have had frequent COPD flare-ups, half have not. The goal is to see if nearby genetic variations affect immune function and infection risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
20-valent pneumococcal conjugate vaccine (PCV20)
What this could lead to
If successful, this study could help identify which patients with alpha-1 antitrypsin deficiency are at higher risk for infections and may benefit from tailored vaccination strategies.
What could go wrong
This is a small, early-stage observational study with only 30 participants, so results may not apply to everyone. It is designed to gather knowledge, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••